Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972887231> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W1972887231 endingPage "206" @default.
- W1972887231 startingPage "S" @default.
- W1972887231 abstract "Introduction Azathioprine intolerance (AZA-I) leads to withdrawal of therapy in up to 30% of patients with IBD. Smaller case series demonstrated that mercaptopurine (MP) could be a well tolerated alternative in selected patients. 1 This study aims to further assess its tolerability, in a larger cohort of AZA-I patients, over a longer period of time, and to re-evaluate potential factors predictive of tolerance. Methods A retrospective audit was made of 137 patients with IBD (78 women, median age at diagnosis 32 years, 78 with CD, 59 with UC) who had been intolerant of AZA and then subsequently treated with MP. Results MP was tolerated by 58% of AZA-I patients (median follow-up 937 days, median dose 0.91 mg/kg). Tolerance was highest in patients with AZA related gastrointestinal intolerance (66%) and hepatotoxicity (61%), and lowest in patients with AZA related flu-like illness (40%). The number of patients with AZA induced neutropenia and pancreatitis were too small to draw firm conclusions (see Abstract PTU-122 table 1). Age at diagnosis was significantly associated with tolerability. Patients intolerant of MP were younger (28 vs 33 yro; p=0.024) and of those under the age of 40 only 55% tolerated MP compared with 69% of those aged 40 years or over (p=Azathioprine-intolerant patients, subsequently treated with mercaptopurine (AZA-I/MP) grouped by azathioprine intolerance Conclusion Consistent with previous data, this, the largest series to date, with substantial follow- up, has shown that MP is a safe alternative for up to 60% of AZA-I patients, including some with a previous major intolerance. Patients with previous gastrointestinal intolerance or hepatotoxicity may be more likely to tolerate a trial of MP. Competing interests None declared. Reference 1. Lees , et al. Aliment Pharmacol & Ther 2007; 27 :220–7." @default.
- W1972887231 created "2016-06-24" @default.
- W1972887231 creator A5005142341 @default.
- W1972887231 creator A5011087661 @default.
- W1972887231 creator A5026827841 @default.
- W1972887231 creator A5033926232 @default.
- W1972887231 creator A5047522708 @default.
- W1972887231 creator A5070160313 @default.
- W1972887231 creator A5074978471 @default.
- W1972887231 date "2012-05-01" @default.
- W1972887231 modified "2023-09-22" @default.
- W1972887231 title "1128 A Trial With Mercaptopurine Following Azathioprine Intolerance is a Safe Treatment Strategy for the Majority of Patients With IBD" @default.
- W1972887231 doi "https://doi.org/10.1016/s0016-5085(12)60771-9" @default.
- W1972887231 hasPublicationYear "2012" @default.
- W1972887231 type Work @default.
- W1972887231 sameAs 1972887231 @default.
- W1972887231 citedByCount "0" @default.
- W1972887231 crossrefType "journal-article" @default.
- W1972887231 hasAuthorship W1972887231A5005142341 @default.
- W1972887231 hasAuthorship W1972887231A5011087661 @default.
- W1972887231 hasAuthorship W1972887231A5026827841 @default.
- W1972887231 hasAuthorship W1972887231A5033926232 @default.
- W1972887231 hasAuthorship W1972887231A5047522708 @default.
- W1972887231 hasAuthorship W1972887231A5070160313 @default.
- W1972887231 hasAuthorship W1972887231A5074978471 @default.
- W1972887231 hasBestOaLocation W19728872311 @default.
- W1972887231 hasConcept C126322002 @default.
- W1972887231 hasConcept C167135981 @default.
- W1972887231 hasConcept C197934379 @default.
- W1972887231 hasConcept C2776670229 @default.
- W1972887231 hasConcept C2776760755 @default.
- W1972887231 hasConcept C2777063308 @default.
- W1972887231 hasConcept C2777173762 @default.
- W1972887231 hasConcept C2778375690 @default.
- W1972887231 hasConcept C2779134260 @default.
- W1972887231 hasConcept C29730261 @default.
- W1972887231 hasConcept C70917649 @default.
- W1972887231 hasConcept C71924100 @default.
- W1972887231 hasConcept C90924648 @default.
- W1972887231 hasConceptScore W1972887231C126322002 @default.
- W1972887231 hasConceptScore W1972887231C167135981 @default.
- W1972887231 hasConceptScore W1972887231C197934379 @default.
- W1972887231 hasConceptScore W1972887231C2776670229 @default.
- W1972887231 hasConceptScore W1972887231C2776760755 @default.
- W1972887231 hasConceptScore W1972887231C2777063308 @default.
- W1972887231 hasConceptScore W1972887231C2777173762 @default.
- W1972887231 hasConceptScore W1972887231C2778375690 @default.
- W1972887231 hasConceptScore W1972887231C2779134260 @default.
- W1972887231 hasConceptScore W1972887231C29730261 @default.
- W1972887231 hasConceptScore W1972887231C70917649 @default.
- W1972887231 hasConceptScore W1972887231C71924100 @default.
- W1972887231 hasConceptScore W1972887231C90924648 @default.
- W1972887231 hasIssue "5" @default.
- W1972887231 hasLocation W19728872311 @default.
- W1972887231 hasOpenAccess W1972887231 @default.
- W1972887231 hasPrimaryLocation W19728872311 @default.
- W1972887231 hasVolume "142" @default.
- W1972887231 isParatext "false" @default.
- W1972887231 isRetracted "false" @default.
- W1972887231 magId "1972887231" @default.
- W1972887231 workType "article" @default.